Patent · US Active

CXCL10 binding proteins and compositions thereof

US11725048B2 · kind B2 · utility

0Cited by

2References

4Claims

0Family size

Assignee

Hudson Institute of Medical Research · AU

Inventors

Andrew Stephens · Denver, US
Adam Rainczuk · Cockatoo, AU
Sung-Woog Kang · Melbourne, AU

Key dates

Filing date	Dec 18, 2020
Grant date	Aug 15, 2023
Priority date	—
Expiry date	Dec 18, 2040

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/54
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and uses thereof in methods of detecting and/or diagnosing a condition in a subject, comprising determining a level of CXCL10 in the subject. Specific antibodies that bind to total CXCL10 (full-length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full-length) were used to measure the level of total and active CXCL10 in samples from ovarian cancer patients. The calculated ratio of active to total CXCL10 was lower in patients with malignant condition when compared to patients with benign tumours or healthy individuals and is the basis of method of diagnosis of malignant conditions, monitoring tumour burden and disease progression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.